DK2148690T3 - Forbindelser ekstraheret fra palmeoliemøllerester til behandlingen af cancer, sammensætninger deraf og fremgangsmåder dermed - Google Patents
Forbindelser ekstraheret fra palmeoliemøllerester til behandlingen af cancer, sammensætninger deraf og fremgangsmåder dermed Download PDFInfo
- Publication number
- DK2148690T3 DK2148690T3 DK08753723.9T DK08753723T DK2148690T3 DK 2148690 T3 DK2148690 T3 DK 2148690T3 DK 08753723 T DK08753723 T DK 08753723T DK 2148690 T3 DK2148690 T3 DK 2148690T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- composition
- treatment
- phenolics
- use according
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 32
- 239000000203 mixture Substances 0.000 title claims description 29
- 201000011510 cancer Diseases 0.000 title claims description 28
- 238000011282 treatment Methods 0.000 title claims description 17
- 235000019482 Palm oil Nutrition 0.000 title claims description 10
- 239000002540 palm oil Substances 0.000 title claims description 10
- 238000000034 method Methods 0.000 title description 13
- 150000001875 compounds Chemical class 0.000 title description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 22
- 229930003427 Vitamin E Natural products 0.000 claims description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 11
- 235000019165 vitamin E Nutrition 0.000 claims description 11
- 239000011709 vitamin E Substances 0.000 claims description 11
- 229940046009 vitamin E Drugs 0.000 claims description 11
- 229930003935 flavonoid Natural products 0.000 claims description 8
- 235000017173 flavonoids Nutrition 0.000 claims description 8
- 150000002215 flavonoids Chemical class 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 235000009048 phenolic acids Nutrition 0.000 claims description 7
- 150000007965 phenolic acids Chemical class 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000011254 conventional chemotherapy Methods 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229930003802 tocotrienol Natural products 0.000 description 6
- 239000011731 tocotrienol Substances 0.000 description 6
- 235000019148 tocotrienols Nutrition 0.000 description 6
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 5
- 241000512897 Elaeis Species 0.000 description 5
- 235000001950 Elaeis guineensis Nutrition 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229940068778 tocotrienols Drugs 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 125000002640 tocopherol group Chemical class 0.000 description 4
- 235000019149 tocopherols Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000002417 nutraceutical Substances 0.000 description 3
- 235000021436 nutraceutical agent Nutrition 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 238000007417 hierarchical cluster analysis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- -1 triterpene alcohols Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- RHUYHJGZWVXEHW-UHFFFAOYSA-N 1,1-Dimethyhydrazine Chemical compound CN(C)N RHUYHJGZWVXEHW-UHFFFAOYSA-N 0.000 description 1
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 101150079049 Ccnd2 gene Proteins 0.000 description 1
- 101150023302 Cdc20 gene Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108091065810 E family Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 101150073031 cdk2 gene Proteins 0.000 description 1
- 230000008235 cell cycle pathway Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 230000004736 colon carcinogenesis Effects 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013075 data extraction Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (7)
1. Sammensætning omfattende phenol, herunder phenolsyrer og flavonoider opnået fra palmeoliemøllerester til anvendelse i behandlingen af cancer ved forebyggelse eller inhibering af proliferationen af cancerceller, hvor canceren er tyktarmscancer eller prostatacancer.
2. Sammensætningen til anvendelse ifølge krav 1, hvor sammensætningen yderligere omfatter vitamin E.
3. Sammensætningen til anvendelse ifølge krav 1, hvor sammensætningen yderligere omfatter en farmaceutisk acceptabel bærer.
4. Sammensætningen til anvendelse ifølge krav 1, hvor behandlingen af cancer yderligere omfatter konventionel kemoterapi eller stråleterapi eller kirurgi.
5. Sammensætningen til anvendelse ifølge krav 1, hvor behandlingen omfatter administration af sammensætningen oralt eller som kosttilskud.
6. Sammensætningen til anvendelse ifølge krav 1, hvor canceren er tyktarmscancer.
7. Sammensætningen til anvendelse ifølge krav 1, hvor canceren er prostatacancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI20070623A MY177206A (en) | 2007-04-23 | 2007-04-23 | Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith |
| PCT/MY2008/000034 WO2008130216A1 (en) | 2007-04-23 | 2008-04-23 | Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2148690T3 true DK2148690T3 (da) | 2015-08-17 |
Family
ID=39875686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08753723.9T DK2148690T3 (da) | 2007-04-23 | 2008-04-23 | Forbindelser ekstraheret fra palmeoliemøllerester til behandlingen af cancer, sammensætninger deraf og fremgangsmåder dermed |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20100197780A1 (da) |
| EP (1) | EP2148690B1 (da) |
| CN (1) | CN101808654B (da) |
| BR (1) | BRPI0811416B1 (da) |
| CO (1) | CO6241128A2 (da) |
| DK (1) | DK2148690T3 (da) |
| HU (1) | HUE025475T2 (da) |
| MY (1) | MY177206A (da) |
| WO (1) | WO2008130216A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY185582A (en) * | 2010-01-07 | 2021-05-24 | Malaysian Palm Oil Board | Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in preventing atheroslerosis and cardiovascular disease |
| MY179036A (en) | 2012-12-13 | 2020-10-26 | Malaysian Palm Oil Board | Anti-proliferative effects of palm vegetation liquor and extracts thereof in preventing pancreatic cancer |
| WO2014189357A1 (en) | 2013-05-21 | 2014-11-27 | Sime Darby Malaysia Berhad | A process for extracting phenolic compound |
| DE102016000198A1 (de) | 2016-01-11 | 2017-08-10 | Christine Apelt | Verfahren zur stofflichen und energetischen Verwertung von flüssigen und feinteiligen Reststoffen der Palmölgewinnung |
| MY196075A (en) * | 2017-06-22 | 2023-03-13 | Univ Putra Malaysia | Oil Palm-Derived Composition for Skin Treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR910004884B1 (ko) * | 1989-02-01 | 1991-07-15 | 한국식품개발연구원 | 유지류의 산화억제방법 |
| US6239114B1 (en) * | 1997-09-26 | 2001-05-29 | Kgk Synergize | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
| JP3763075B2 (ja) * | 1998-04-24 | 2006-04-05 | サンスター株式会社 | 歯周病の予防又は治療用の食品組成物、口腔用組成物及び医薬組成物 |
| MY134878A (en) * | 1998-09-24 | 2007-12-31 | Palm Oil Res And Dev Board | Treatment of liquors derived from oil-bearing fruit. |
| GB0026018D0 (en) | 2000-10-24 | 2000-12-13 | Novartis Nutrition Ag | New composition |
| MY169539A (en) * | 2007-04-12 | 2019-04-22 | Malaysian Palm Oil Board | Palm phenolics and flavonoids as potent biological and chemical antioxidants for applications in foods and edible oils |
-
2007
- 2007-04-23 MY MYPI20070623A patent/MY177206A/en unknown
-
2008
- 2008-04-23 WO PCT/MY2008/000034 patent/WO2008130216A1/en active Application Filing
- 2008-04-23 BR BRPI0811416-1A patent/BRPI0811416B1/pt active IP Right Grant
- 2008-04-23 EP EP08753723.9A patent/EP2148690B1/en active Active
- 2008-04-23 CN CN2008800192396A patent/CN101808654B/zh not_active Expired - Fee Related
- 2008-04-23 DK DK08753723.9T patent/DK2148690T3/da active
- 2008-04-23 US US12/596,977 patent/US20100197780A1/en not_active Abandoned
- 2008-04-23 HU HUE08753723A patent/HUE025475T2/en unknown
-
2009
- 2009-11-12 CO CO09129031A patent/CO6241128A2/es not_active Application Discontinuation
-
2014
- 2014-12-08 US US14/564,014 patent/US20150196614A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008130216A1 (en) | 2008-10-30 |
| US20100197780A1 (en) | 2010-08-05 |
| EP2148690B1 (en) | 2015-08-05 |
| CN101808654A (zh) | 2010-08-18 |
| BRPI0811416B1 (pt) | 2022-05-17 |
| US20150196614A1 (en) | 2015-07-16 |
| HUE025475T2 (en) | 2016-02-29 |
| CN101808654B (zh) | 2012-11-14 |
| CO6241128A2 (es) | 2011-01-20 |
| EP2148690A4 (en) | 2010-06-16 |
| MY177206A (en) | 2020-09-09 |
| BRPI0811416A2 (pt) | 2015-06-16 |
| EP2148690A1 (en) | 2010-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rengasamy et al. | The role of flavonoids in autoimmune diseases: Therapeutic updates | |
| Zhou et al. | Recent advances of natural polyphenols activators for Keap1‐Nrf2 signaling pathway | |
| Saini et al. | Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: An update on epidemiological and mechanistic perspectives | |
| Liczbiński et al. | Molecular mechanism of curcumin action in signaling pathways: Review of the latest research | |
| Zaplatic et al. | Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer's disease | |
| Xian et al. | Emerging perspective: role of increased ROS and redox imbalance in skin carcinogenesis | |
| Lee et al. | Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression | |
| US20150196614A1 (en) | Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith | |
| Tuli et al. | Natural flavonoids exhibit potent anticancer activity by targeting microRNAs in cancer: A signature step hinting towards clinical perfection | |
| Dey et al. | Natural compounds as therapeutic agents in the treatment cystic fibrosis | |
| Xiao et al. | The potential health benefits of aloin from genus Aloe | |
| Kim et al. | Antiproliferative effect of vine stem extract from Spatholobus suberectus Dunn on rat C6 glioma cells through regulation of ROS, mitochondrial depolarization, and P21 protein expression | |
| Li et al. | Tea polyphenols alleviate hydrogen peroxide‑induced oxidative stress damage through the Mst/Nrf2 axis and the Keap1/Nrf2/HO‑1 pathway in murine RAW264. 7 cells | |
| Tuli et al. | Wogonin, as a potent anticancer compound: From chemistry to cellular interactions | |
| Meilawati et al. | Scopoletin: anticancer potential and mechanism of action | |
| Neto et al. | Triplaris gardneriana seeds extract exhibits in vitro anti-inflammatory properties in human neutrophils after oxidative treatment | |
| Hu et al. | Curcumin derived from medicinal homologous foods: its main signals in immunoregulation of oxidative stress, inflammation, and apoptosis | |
| Malik et al. | Therapeutic implications of Nigella sativa against cancer metastasis. | |
| Kojima-Yuasa | Biological and pharmacological effects of polyphenolic compounds from Ecklonia cava | |
| Zhang et al. | New perspectives on the therapeutic potential of quercetin in non-communicable diseases: Targeting Nrf2 to counteract oxidative stress and inflammation | |
| Chu et al. | Anticancer activity and mediation of apoptosis in hepatoma carcinoma cells induced by djulis and its bioactive compounds | |
| Mustafa | Nutraceutical-based telomerase inhibitors: Renewed hope for cancer therapy | |
| JP4903558B2 (ja) | ガンマ−トコトリエノールによる放射線防護 | |
| Bouyahya et al. | Bioactive compounds from nature: Antioxidants targeting cellular transformation in response to epigenetic perturbations induced by oxidative stress | |
| Ahire et al. | Ellagic acid radiosensitizes tumor cells by evoking apoptotic pathway |